Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PeptiCrad

Financiado

Cerrado

Personalized oncolytic vaccines for cancer immunotherapy

This grant application proposes to develop a novel, customizable and personalized anti-cancer vaccine: peptide-coated conditionally replicating adenovirus (PeptiCrad). Anti-cancer vaccines represent a promising approach for cancer... ver más

30/06/2022

HELSINGIN YLIOPIST...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

HELSINGIN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-06-30

ERC-CoG-2015: ERC Consolidator Grant

I+D

Cerrada hace 9 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

HELSINGIN YLIOPISTO

1.98M€ | Lider

OBRASCON HUARTE LAIN,

336.41K€ | Participante

Proyectos interesantes

DCanVAX

Medical Technol...

Data Science

Cerrado

EUIN2013-51221

Medical Technol...

Data Science

15K€ Cerrado

SPLITVAC

Medical Technol...

Data Science

173K€ Cerrado

PanCaVax

Medical Technol...

Data Science

71K€ Cerrado

PID2019-109102RA-I00

Medical Technol...

Data Science

145K€ Cerrado

VIRAL&IMMUNE THERAPY

Medical Technol...

Data Science

154K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 72 meses Fecha Inicio: 2016-06-06
Fecha Fin: 2022-06-30

Líder del proyecto

HELSINGIN YLIOPISTO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto This grant application proposes to develop a novel, customizable and personalized anti-cancer vaccine: peptide-coated conditionally replicating adenovirus (PeptiCrad). Anti-cancer vaccines represent a promising approach for cancer treatment because they elicit durable and specific immune response that destroys primary tumors and distant metastases. Oncolytic viruses (OVs) are of significant interest because in addition to cytolysis they stimulate anti-tumor immune responses, thereby functioning as anti-tumor vaccines. However, their efficacy among cancer patients has been modest. One reason for this shortcoming is that the immune responses generated by virus infection primarily target the virus rather than the tumor. In addition, tumors differ across patients. Specific and personalized approaches (rather than generic virus infection strategies) are required to optimize therapy. To this end we propose to develop a novel vaccine platform that combines the strengths of OVs with the specificity of vaccines. Our technology is called PeptiCrad. PeptiCrad is a virus dressed as a tumor. It directly kills cancer cells (i.e., oncolytic viruses) and expresses immunomodulatory molecules (i.e., cytokines or the immune checkpoint inhibitors anti-CTLA4 or anti-PDL1); most importantly, it diverts immunity toward the tumor (i.e., the capsid becomes covered with MHC-I-restricted tumor-specific peptides). The method that we have developed to cover the virus with tumor peptides is novel and exceeds current state-of-the-art. Importantly, it is fast and does not require genetic or chemical manipulation of the virus; this feature has a significant impact on the translational capability of the project. Our preliminary results show great potential but significant questions regarding the development and the personalization of PeptiCrad remain to be studied. In this grant I propose two lines of research, one focused on the development and the other one on the personalization of PeptiCrad.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores